We are striving to make innovative, high-end biotherapeutics more
affordable through a game-changing mRNA platform.
De novo Biotherapeutics’ primary target indication is for the
treatment of relapsed or refractory cancers, It is designing and
building a couple of mRNA engagers with new targets,
and will prioritize top three lead candidates aiming to initiate
phase 1 clinical study at the end of 2023.
De novo Biotherapeutics’ primary target indication is for the
treatment of relapsed or refractory cancers, It is designing and
building a couple of mRNA engagers with new targets,
and will prioritize top three lead candidates aiming to initiate
phase 1 clinical study at the end of 2023.
We will inform you of the latest
news of De novo Biotherapeutics
